Wockhardt Ltd is an Indian pharmaceutical company focused on specialty injectables, branded generics, biosimilar insulins, and novel antibiotic drug discovery, operating across the UK, emerging markets, India, and the US. In FY26 the company reported consolidated revenue of INR 3,373 Cr, with EBITDA growing 51% year-on-year to INR 630 Cr. Wockhardt became the first Indian company to have an India-discovered drug - Zaynich (cefepime-zidebactam) - approved by the US FDA, marking a landmark in its novel antimicrobial resistance pipeline.[1][2]
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
Sign in to see dividends, bonuses and splits - free.
Sign in